Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors.

Kojima T, Yamazaki K, Kato K, Muro K, Hara H, Chin K, Goddemeier T, Kuffel S, Watanabe M, Doi T.

Cancer Sci. 2018 Aug 12. doi: 10.1111/cas.13767. [Epub ahead of print]

2.

Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.

Yen CJ, Muro K, Kim TW, Kudo M, Shih JY, Lee KW, Chao Y, Kim SW, Yamazaki K, Sohn J, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Chung HC.

J Glob Oncol. 2018 Jul;(4):1-12. doi: 10.1200/JGO.17.00227.

PMID:
30085888
3.

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study.

Honda K, Gyawali B, Ando M, Sugiyama K, Mitani S, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K.

Ecancermedicalscience. 2018 Jul 5;12:847. doi: 10.3332/ecancer.2018.847. eCollection 2018.

4.

LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer.

Catenacci Daniel V, Wainberg Z, Fuchs Charles S, Garrido M, Bang YJ, Muro K, Savage M, Wang J, Koshiji M, Dalal Rita P, Kang YK.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.008. No abstract available.

PMID:
30052791
5.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R.

Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.

PMID:
29955135
6.

Correction to: Comprehensive Registry of Esophageal Cancer in Japan, 2011.

Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, Oyama T, Toh Y, Udagawa H, Uno T; Registration Committee for Esophageal Cancer of the Japan Esophageal Society.

Esophagus. 2018 Jun 12. doi: 10.1007/s10388-018-0624-x. [Epub ahead of print]

PMID:
29948478
7.

Comprehensive Registry of Esophageal Cancer in Japan, 2011.

Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, Oyama T, Toh Y, Udagawa H, Uno T; Registration Committee for Esophageal Cancer of the Japan Esophageal Society.

Esophagus. 2018 Jul;15(3):127-152. doi: 10.1007/s10388-018-0614-z. Epub 2018 Apr 18. No abstract available. Erratum in: Esophagus. 2018 Jun 12;:.

8.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators.

Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.

PMID:
29880231
9.

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition.

Yamazaki K, Taniguchi H, Yoshino T, Akagi K, Ishida H, Ebi H, Nakatani K, Muro K, Yatabe Y, Yamaguchi K, Tsuchihara K.

Cancer Sci. 2018 Jun;109(6):2074-2079. doi: 10.1111/cas.13617.

10.

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.

Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Fujii H, Muro K, Esaki T, Choda Y, Takano T, Chin K, Sato A, Goto M, Fukushima N, Hara T, Machida N, Ohta M, Boku N, Shimura M, Morita S, Koizumi W.

Gastric Cancer. 2018 May 31. doi: 10.1007/s10120-018-0838-6. [Epub ahead of print]

PMID:
29855738
11.

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set.

Grothey A, Yoshino T, Bodoky G, Ciuleanu T, Garcia-Carbonero R, García-Alfonso P, Van Cutsem E, Muro K, Mytelka DS, Li L, Lipkovich O, Hsu Y, Sashegyi A, Ferry D, Nasroulah F, Tabernero J.

ESMO Open. 2018 Apr 24;3(3):e000347. doi: 10.1136/esmoopen-2018-000347. eCollection 2018.

12.

Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging.

Murata S, Matsushima S, Sato Y, Yamaura H, Kato M, Hasegawa T, Muro K, Inaba Y.

Abdom Radiol (NY). 2018 Apr 17. doi: 10.1007/s00261-018-1615-z. [Epub ahead of print]

PMID:
29666951
13.

Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.

Kondoh C, Kadowaki S, Komori A, Narita Y, Taniguchi H, Ura T, Ando M, Muro K.

Gastric Cancer. 2018 Apr 16. doi: 10.1007/s10120-018-0825-y. [Epub ahead of print]

PMID:
29658055
14.

Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale.

Masuishi T, Taniguchi H, Sugiyama K, Kato K, Mitani S, Honda K, Narita Y, Kadowaki S, Ura T, Ando M, Muro K.

Ann Oncol. 2018 May 1;29(5):1330-1331. doi: 10.1093/annonc/mdy107. No abstract available.

PMID:
29635451
15.

Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients.

Narita Y, Kadowaki S, Oze I, Kito Y, Kawakami T, Machida N, Taniguchi H, Ura T, Ando M, Ito S, Tajika M, Yatabe Y, Yasui H, Muro K.

J Gastrointest Oncol. 2018 Feb;9(1):52-63. doi: 10.21037/jgo.2017.11.08.

16.

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.

Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW.

Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16.

PMID:
29555258
17.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH.

JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10.

18.

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.

Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A.

Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9.

19.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E.

Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5.

PMID:
29431699
20.

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T.

Ann Oncol. 2018 Apr 1;29(4):1004-1009. doi: 10.1093/annonc/mdy040.

PMID:
29408977
21.

First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.

Makiyama A, Kunieda K, Noguchi M, Kajiwara T, Tamura T, Takeda K, Sugiyama J, Minashi K, Moriwaki T, Sugimoto N, Nagase M, Negoro Y, Tsuda T, Shimodaira H, Okano N, Tsuji A, Sakai D, Yanagihara K, Ueda S, Tamura S, Otsu S, Honda T, Matsushita Y, Okuno T, Kashiwada T, Nozaki A, Ebi M, Okuda H, Shimokawa M, Hironaka S, Hyodo I, Baba E, Boku N, Muro K, Esaki T.

Gastric Cancer. 2018 Sep;21(5):792-801. doi: 10.1007/s10120-018-0797-y. Epub 2018 Jan 20.

PMID:
29353332
22.

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.

Kato K, Ura T, Koizumi W, Iwasa S, Katada C, Azuma M, Ishikura S, Nakao Y, Onuma H, Muro K.

Cancer Sci. 2018 Mar;109(3):785-793. doi: 10.1111/cas.13481. Epub 2018 Feb 15.

23.

Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.

Tahara M, Muro K, Hasegawa Y, Chung HC, Lin CC, Keam B, Takahashi K, Cheng JD, Bang YJ.

Cancer Sci. 2018 Mar;109(3):771-776. doi: 10.1111/cas.13480. Epub 2018 Feb 8.

24.

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.

Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, Longo-Munoz F, Portales F, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y, Makris L, Loehrer P, Lenz HJ, Ohtsu A; RECOURSE Study Group.

Eur J Cancer. 2018 Feb;90:63-72. doi: 10.1016/j.ejca.2017.10.009. Epub 2017 Dec 21.

25.

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.

Tabernero J, Hozak RR, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Prausová J, Muro K, Siegel RW, Konrad RJ, Ouyang H, Melemed SA, Ferry D, Nasroulah F, Van Cutsem E.

Ann Oncol. 2018 Mar 1;29(3):602-609. doi: 10.1093/annonc/mdx767.

26.

FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.

Masuishi T, Kadowaki S, Kondo M, Komori A, Sugiyama K, Mitani S, Honda K, Narita Y, Taniguchi H, Ura T, Ando M, Mishima H, Muro K.

Anticancer Res. 2017 Dec;37(12):7037-7042.

PMID:
29187492
27.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.

Ann Oncol. 2018 Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738.

PMID:
29155929
28.

[Lower G. I./Colon and Rectum Cancer Updated Japanese Guidelines in Colon and Rectum Cancer].

Muro K.

Gan To Kagaku Ryoho. 2017 Nov;44(11):984-985. Japanese. No abstract available.

PMID:
29138372
29.

Clinical Features of Regorafenib-induced Liver Injury in Japanese Patients From Postmarketing Experience.

Uetake H, Sugihara K, Muro K, Sunaya T, Horiuchi-Yamamoto Y, Takikawa H.

Clin Colorectal Cancer. 2018 Mar;17(1):e49-e58. doi: 10.1016/j.clcc.2017.09.004. Epub 2017 Sep 28.

30.

Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature.

Honda K, Ando M, Sugiyama K, Mitani S, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K.

Case Rep Oncol. 2017 Sep 21;10(3):863-870. doi: 10.1159/000481194. eCollection 2017 Sep-Dec.

31.

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT.

Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.

PMID:
28993052
32.

A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer.

Doi T, Yamaguchi K, Komatsu Y, Muro K, Nishina T, Nakajima TE, Tang R, Yang H, Zhang Y, Jung AS, Ang A, Yasui H.

Jpn J Clin Oncol. 2017 Nov 1;47(11):1002-1009. doi: 10.1093/jjco/hyx114.

PMID:
28973403
33.

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.

34.

Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy.

Ito M, Kodaira T, Tachibana H, Tomita N, Makita C, Koide Y, Kato D, Abe T, Muro K, Tajika M, Niwa Y, Hasegawa Y.

Head Neck. 2017 Dec;39(12):2406-2415. doi: 10.1002/hed.24909. Epub 2017 Sep 27.

PMID:
28960561
35.

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.

Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C.

J Gastroenterol Hepatol. 2018 Apr;33(4):814-824. doi: 10.1111/jgh.14007. Epub 2018 Feb 1.

PMID:
28960444
36.

[I. Immunotherapy for Gastroenterological Cancer].

Narita Y, Muro K.

Gan To Kagaku Ryoho. 2017 Sep;44(9):743-747. Japanese. No abstract available.

PMID:
28912401
37.

Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin.

Maeda A, Ando H, Ura T, Muro K, Aoki M, Saito K, Kondo E, Takahashi S, Ito Y, Mizuno Y, Fujimura A.

Anticancer Res. 2017 Sep;37(9):5235-5239.

PMID:
28870959
38.

Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.

Komori A, Taniguchi H, Hamauchi S, Masuishi T, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K.

Oncology. 2017;93(5):329-335. doi: 10.1159/000479280. Epub 2017 Sep 2.

PMID:
28866662
39.

Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.

Kadowaki S, Masuishi T, Eto T, Narita Y, Taniguchi H, Ura T, Ando M, Tajika M, Niwa Y, Yatabe Y, Muro K.

Cancer Chemother Pharmacol. 2017 Oct;80(4):807-813. doi: 10.1007/s00280-017-3422-6. Epub 2017 Aug 18.

PMID:
28821938
40.

Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer.

Narita Y, Kadowaki S, Masuishi T, Taniguchi H, Takahari D, Ura T, Ando M, Tajika M, Niwa Y, Eto T, Hara H, Asayama M, Yamaguchi K, Yatabe Y, Muro K.

Oncol Lett. 2017 Aug;14(2):2545-2551. doi: 10.3892/ol.2017.6409. Epub 2017 Jun 19.

41.

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study.

Baba H, Yamada Y, Takahari D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K.

ESMO Open. 2017 Mar 9;2(1):e000135. doi: 10.1136/esmoopen-2016-000135. eCollection 2017.

42.

Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.

Iizumi S, Takashima A, Narita Y, Tajika M, Muro K, Kawai S, Yasui H, Matsushima T, Takahari D, Nagashima K, Boku N.

Cancer Chemother Pharmacol. 2017 Sep;80(3):575-582. doi: 10.1007/s00280-017-3397-3. Epub 2017 Jul 20.

PMID:
28730292
43.

Comprehensive Registry of Esophageal Cancer in Japan, 2010.

Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, Oyama T, Toh Y, Udagawa H, Uno T; Registration Committee for Esophageal Cancer of the Japan Esophageal Society.

Esophagus. 2017;14(3):189-214. doi: 10.1007/s10388-017-0578-4. Epub 2017 May 19. No abstract available.

44.

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.

Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS.

Mol Cancer Ther. 2017 Oct;16(10):2215-2222. doi: 10.1158/1535-7163.MCT-16-0895. Epub 2017 Jul 17.

PMID:
28716815
45.

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.

Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC, Safran H, Bodoky G, Chau I, Shimada Y, Al-Batran SE, Passalacqua R, Ohtsu A, Emig M, Ferry D, Chandrawansa K, Hsu Y, Sashegyi A, Liepa AM, Wilke H.

J Gastric Cancer. 2017 Jun;17(2):132-144. doi: 10.5230/jgc.2017.17.e16. Epub 2017 Jun 16.

46.

Systemic chemotherapy for metastatic colorectal cancer -Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for treatment of colorectal cancer.

Muro K.

Nihon Shokakibyo Gakkai Zasshi. 2017;114(7):1217-1223. doi: 10.11405/nisshoshi.114.1217. Japanese. No abstract available.

PMID:
28679979
47.

Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.

Shitara K, Kadowaki S, Nishina T, Sakai D, Yoshikawa R, Piao Y, Ozeki A, Inoue K, Gritli I, Muro K.

Gastric Cancer. 2018 Jan;21(1):106-113. doi: 10.1007/s10120-017-0745-2. Epub 2017 Jun 30.

PMID:
28667466
48.

Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.

Mitani S, Kadowaki S, Komori A, Sugiyama K, Narita Y, Taniguchi H, Ura T, Ando M, Sato Y, Yamaura H, Inaba Y, Ishihara M, Tanaka T, Tajika M, Muro K.

Medicine (Baltimore). 2017 Jun;96(22):e6874. doi: 10.1097/MD.0000000000006874. Review.

49.

No benefit from ramucirumab in first-line chemotherapy?

Mitani S, Muro K.

Transl Gastroenterol Hepatol. 2017 Apr 21;2:30. doi: 10.21037/tgh.2017.03.18. eCollection 2017. No abstract available.

50.

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.

Kumthekar P, Grimm S, Chandler J, Mehta M, Marymont M, Levy R, Muro K, Helenowski I, McCarthy K, Fountas L, Raizer J.

J Neurooncol. 2017 Jul;133(3):589-594. doi: 10.1007/s11060-017-2469-x. Epub 2017 May 16.

PMID:
28510787

Supplemental Content

Support Center